Harnessing multi-omic profiling and proprietary AI to create truly individualized cancer treatments — designed for each patient's unique tumor.
Discover Our Approach →From biopsy to personalized treatment in 45 days, a truly scalable advanced manufacturing platform.
We analyze the individual patient's cancer cells using comprehensive DNA/RNA sequencing combined with advanced mass spectrometry.
Our proprietary BreakBioAI platform ranks 40+ mutated and non-mutated unique targets from each patient's tumor cells.
Every patient receives a customized peptide immunotherapy to stimulate T-cells for their specific targets.
Beginning in 2026, BreakBio is currently enrolling patients for our first trial targeting Triple Negative Breast Cancer (TNBC).
Pioneers in cancer research, AI, proteomics, and personalized medicine.
Roy de Souza had built a successful career in technology, founding ZEDO — one of the world's largest ad-serving platforms. But in 2017, when his wife Aisha de Sequeira was diagnosed with metastatic colon cancer, everything changed.
Rather than accept limited conventional options, Roy spent six months studying cancer research intensively. He partnered with leading scientists to develop a personalized cancer vaccine for Aisha — one that had to be manufactured and administered in Germany because U.S. regulations didn't yet allow it.
That experience revealed how far behind cancer treatment was compared to what technology could enable — and it sparked the creation of BreakBio. Roy and Aisha were honored by the American Cancer Society in 2023 for their contributions to advancing personalized cancer treatment.
A documentary about their journey is being produced by USC professor Alex Rotaru.
BreakBio is the third player in personalized drugs after Moderna and BioNTech and the top private company in the personalized drugs space with advanced cutting edge technology and clinical trials. BreakBio's treatment is designed for higher efficacy than Moderna or BioNTech and it is also designed to treat more cancer indications than Moderna or BioNTech.
BreakBio is designed for higher efficacy than Moderna's Individualized Neoantigen Therapy (INT). Higher efficacy because BreakBio is designed to find more and better targets per patient. It is an AI first biotech company. For every patient, its platform integrates the highest quality tumor DNA sequencing, RNA sequencing, mass-spectrometry-based immunopeptidomics (of that patient) with proprietary deep AI analysis to find better targets on that patient's cancer cells. Better targets means killing more (or all) of the cancer cells.
BreakBio is designed to extend personalized drugs to more cancer indications. BreakBio achieves this by targeting not just neoantigens (associated with mutations as Moderna and BioNTech do) but it also searches for and finds, in each patient, some of the hundreds of cancer-associated non-mutated proteins such as cancer testis antigens, embryonic antigens, etc - so BreakBio is designed to also work for low mutational cancers, which means it is designed to work for all solid cancers both high mutational cancers like melanoma and low mutational cancers like colorectal.